5 completed, 2 terminated, 1 enrolling by invitation. 3 Not applicable, 3 Phase 3, 1 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 3 | Completed 2, Enrolling by invitation 1 |
| Phase 3 | 3 | Terminated 2, Completed 1 |
| Phase 2 | 1 | Completed 1 |
| Phase 4 | 1 | Completed 1 |
Follow Polysorbates: new trials by email Literature Review of Polysorbates trials Research Report on Polysorbates
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The T1D Talks Pilot Study The T1D Talks: A Virtual Group for Teens and Tweens with T1D - Type 1 Diabetes (T1D) | Not applicable | Enrolling by invitation | Western Michigan University School of Medicine | 18 | 2024-02-15 | 2025-08-07 |
| Compare the Efficacy and the Safety of Taxotere and Nanoxel M as Neoadjuvant Chemotherapy in Breast Cancer Nanoxel M, Taxotere, Doxorubicin - Breast Cancer | Phase 3 | Terminated | Samyang Biopharmaceuticals Corporation | 26 | 2022-03-31 | 2024-05-17 |
| A Study to Evaluate the Efficacy and Safety of ORMD-0801 (Oral Insulin) in Patients With Type 2 Diabetes Mellitus Cohort A: ORMD-0801, Placebo oral capsule, Cohort B: ORMD-0801 - T2DM (Type 2 Diabetes Mellitus) | Phase 2 | Completed | Oramed, Ltd. | 373 | 2018-05-29 | 2022-11-08 |
| Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC Nanoxel®M, Mitomycin-C - Non Muscle Invasive Bladder Cancer | Phase 3 | Terminated | Samyang Biopharmaceuticals Corporation | 36 | 2017-01-01 | 2019-08-30 |
| Efficacy and Safety of Adalimumab in Patients With Psoriasis and Obstructive Sleep Apnea Adalimumab, Placebo - Psoriasis, Sleep Apnea, Obstructive | Phase 4 | Completed | Innovaderm Research Inc. | 20 | 2010-09-01 | 2011-10-28 |
| Safety and Efficacy of Two Artificial Tears in Dry Eye Subjects Glycerin and Polysorbate 80 based artificial tear, Formulation 1: Carboxymethylcellulose sodium, glycerin and Polysorbate 80, based artificial tear, Formulation 2: Carboxymethylcellulose sodium, glycerin, and Polysorbate 80 based artificial tear - Dry Eye Syndrome | Not applicable | Completed | Allergan | 288 | 2009-11-01 | 2015-08-17 |
| Safety and Tolerability of Artificial Tears in Dry Eye Subjects Formulation 1: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear, Formulation 2: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear, Glycerin and Polysorbate 80 based artificial tear - Dry Eye Syndrome | Not applicable | Completed | Allergan | 47 | 2009-08-01 | 2015-08-26 |
| Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants 13 valent pneumococcal conjugate vaccine with Polysorbate 80, 13 valent pneumococcal conjugate vaccine without Polysorbate 80 - Vaccines, Pneumococcal | Phase 3 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 500 | 2006-11-01 | 2012-08-15 |
Dry Eye Syndromes (2) · Breast Neoplasms (1) · Carcinoma, Transitional Cell (1) · Diabetes Mellitus, Type 1 (1) · Diabetes Mellitus, Type 2 (1) · Emotional Regulation (1) · Non-Muscle Invasive Bladder Neoplasms (1) · Obesity (1) · Psoriasis (1) · Sleep Apnea, Obstructive (1)
Allergan (2) · Samyang Biopharmaceuticals Corporation (2) · Innovaderm Research Inc. (1) · Oramed, Ltd. (1) · Western Michigan University School of Medicine (1) · Wyeth is now a wholly owned subsidiary of Pfizer (1)
United States (4) · South Korea (2) · Canada (1) · Poland (1)
Ja Hyeon Ku (1) · Joel M Neutel, M. D. (1) · Joohyuk Sohn, M.D.,Ph.D. (1) · Rachel Wasserman, PhD (1) · Robert Bissonnette, MD, FRCPC (1)